Nerlynx (neratinib) — Medica
Breast cancer – adjuvant therapy (early-stage HER2-positive)
Initial criteria
- age ≥ 18 years
- will not be used in combination with HER2 antagonists (e.g., trastuzumab, pertuzumab)
- HER2-positive breast cancer
- EITHER extended adjuvant therapy following completion of 1 year of adjuvant intravenous trastuzumab OR patient tried adjuvant intravenous trastuzumab and could not tolerate 1 year of therapy
Approval duration
1 year